US09058V1035
© Globe Newswire
12.12.2025
BCRX
LISTED
NASDAQ
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
News Preview
–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P–...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
BCRX
LISTED
NASDAQ
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
News Preview
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to BioCryst’s proposed acquisition of Astria Therapeutic...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
05.11.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as o...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
03.11.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— ...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2025
BCRX
LISTED
NASDAQ
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
News Preview
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will inclu...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
BCRX
LISTED
NASDAQ
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
News Preview
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio –...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and restricted stock units (RSUs) covering an aggregate of 91,4...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
BCRX
LISTED
NASDAQ
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
News Preview
– Transaction valued at $250 million, with up to $14 million in future milestones –...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 71,40...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
BCRX
LISTED
NASDAQ
BioCryst Announces Departure of Dr. Helen Thackray
News Preview
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.08.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
News Preview
—Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)—...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
31.07.2025
BCRX
LISTED
NASDAQ
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
News Preview
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company’s chief comm...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.07.2025
BCRX
LISTED
NASDAQ
BioCryst to Report Second Quarter 2025 Financial Results on August 4
News Preview
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.07.2025
BCRX
LISTED
NASDAQ
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
News Preview
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as o...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2025
BCRX
LISTED
NASDAQ
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
News Preview
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones—...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.06.2025
BCRX
LISTED
NASDAQ
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
News Preview
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2025
BCRX
LISTED
NASDAQ
ORLADEYO® (berotralstat) Approved in Colombia
News Preview
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and ped...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
BCRX
LISTED
NASDAQ
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
News Preview
ORLADEYO® (berotralstat) now reimbursed in the Netherlands ORLADEYO® (berotralstat) now reimbursed in the Netherlands...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as o...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
BCRX
LISTED
NASDAQ
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
News Preview
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasg...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
BCRX
LISTED
NASDAQ
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
News Preview
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.05.2025
BCRX
LISTED
NASDAQ
BioCryst to Present at Upcoming Investor Conferences
News Preview
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2025
BCRX
LISTED
NASDAQ
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
News Preview
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
BCRX
LISTED
NASDAQ
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
News Preview
—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)—...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 48,000 shares of BioCryst common stock. The RSUs were granted as of...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2025
BCRX
LISTED
NASDAQ
BioCryst Appoints Steve Frank to Board of Directors
News Preview
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
BCRX
LISTED
NASDAQ
BioCryst to Present at Upcoming Investor Conferences
News Preview
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
BCRX
LISTED
NASDAQ
BioCryst to Report First Quarter 2025 Financial Results on May 5
News Preview
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.04.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
News Preview
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)—...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
BCRX
LISTED
NASDAQ
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
News Preview
–Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function–...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
BCRX
LISTED
NASDAQ
BioCryst to Present at Upcoming Investor Conferences
News Preview
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.02.2025
BCRX
LISTED
NASDAQ
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
News Preview
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patie...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.02.2025
BCRX
LISTED
NASDAQ
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
News Preview
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.02.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 22,575 shares, and restricted stock units (RSUs) covering an aggregate of 27,55...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
BCRX
LISTED
NASDAQ
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
News Preview
—ORLADEYO net revenue expected to be between $515-$535 million in 2025—...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
BCRX
LISTED
NASDAQ
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 52,750 shares, and restricted stock units (RSUs) covering an aggregate of 36,975 s...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 17,400 shares, and restricted stock units (RSUs) covering an aggregate of 12,150...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
BCRX
LISTED
NASDAQ
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
News Preview
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
BCRX
LISTED
NASDAQ
BioCryst to Present at Upcoming Investor Conferences
News Preview
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
News Preview
— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) —...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
BCRX
LISTED
NASDAQ
BioCryst to Report Third Quarter 2024 Financial Results on November 4
News Preview
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2024
BCRX
LISTED
NASDAQ
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
News Preview
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource uti...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 21 newly-hired employees stock options to purchase an aggregate of 71,175 shares, and restricted stock units (RSUs) covering an aggregate of 50,025 s...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2024
BCRX
LISTED
NASDAQ
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
News Preview
—Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic—...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
BCRX
LISTED
NASDAQ
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
News Preview
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded BioCryst up to a $69 million contract for the procurement of up to 95,625 doses over a five-year period of RAPIVAB® (peramivir injection) for the tre...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
BCRX
LISTED
NASDAQ
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
News Preview
INTENDED FOR CANADIAN AUDIENCES ONLY...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2024
BCRX
LISTED
NASDAQ
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
News Preview
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their here...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 28,400 shares, and restricted stock units (RSUs) covering an aggregate of 20,02...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
BCRX
LISTED
NASDAQ
BioCryst to Present at Upcoming Investor Conferences
News Preview
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
News Preview
—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million—...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.08.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 40,350 shares, and restricted stock units (RSUs) covering an aggregate of 28,200...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2024
BCRX
LISTED
NASDAQ
BioCryst to Report Second Quarter 2024 Financial Results on August 5
News Preview
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2024
BCRX
LISTED
NASDAQ
ORLADEYO® (berotralstat) Approved in Peru
News Preview
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pe...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 46,850 shares, and restricted stock units (RSUs) covering an aggregate of 19,435...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
